Hagop Kantarjian, MD, on Treating Philadelphia Chromosome–Positive ALL
2014 ASH Annual MeetingHagop Kantarjian, MD, of The University of Texas MD Anderson Cancer Center, offers his thoughts on abstract 797, “First Results of the Multicenter Total Therapy Gimema LAL 1509 Protocol for De Novo Adult Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia Patients,” presented by Sabina Chiaretti, MD, PhD, and abstract 798, “Nilotinib and Chemotherapy for First-Line Treatment in Elderly Patients with De Novo Philadelphia Chromosome/BCR-ABL1–Positive Acute Lymphoblastic Leukemia (ALL): A Trial of the European Working Group for Adult ALL (EWALL-PH-02),” presented by Oliver G. Ottman, MD.
Related Videos
Laurie Sehn, MD, on Brentuximab Vedotin in Diffuse Large B-Cell Lymphoma With Undetectable CD30
Laurie Sehn, MD, of the BC Cancer Agency, on abstract 629, “Brentuximab Vedotin Monotherapy in ...
Bertrand Coiffier, MD, PhD, on the Phase III LyMa Trial
Bertrand Coiffier, MD, PhD, of Centre Hospitalier Lyon-Sud, offers his thoughts on abstract 146, “
Alan F. List, MD, of Moffitt Cancer Center, offers his thoughts on abstract 163, “Overall Survi...
Alan F. List, MD, on Rigosertib in Relapsed/Refractory Higher-Risk Myelodysplastic Syndrome
Hagop Kantarjian, MD, on Blinatumomab in Precursor B-Cell ALL
Hagop Kantarjian, MD, of The University of Texas MD Anderson Cancer Center, offers his thoughts on abstract 379,
Laurie Sehn, MD, of the BC Cancer Agency, on abstract 625, “Sustained Remission With the Combin...
Laurie Sehn, MD, on Lenalidomide Plus Rituximab in Previously Untreated Mantle Cell Lymphoma
